Goldman Sachs starts coverage of Elanco Animal Health stock with USD 32.00 target
Published on 10/17/2026 at 22:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and earnings date
- Goldman Sachs began coverage with a USD 32.00 target on October 16, 2026.
- Second-quarter revenue reached USD 1.37 billion.
- Elanco Animal Health stock closed at USD 23.55 at 4:00 p.m. ET on October 16, 2026, up 0.04 percent from its prior close.
- Elanco plans to report third-quarter 2026 results on November 6, 2026.
Goldman Sachs began coverage of Elanco Animal Health with a Buy rating and a USD 32.00 price target on October 16, 2026, according to Markets Insider. The target is 35.88 percent above the NYSE closing price of USD 23.55 on that date. Elanco Animal Health stock ended at USD 23.55 at 4:00 p.m. ET, up 0.04 percent from its prior close.
Second-quarter revenue sets the base
Elanco reported USD 1.37 billion in revenue for the second quarter of 2026. The figure came from the companys latest reported quarter, while MarketBeat listed USD 0.34 as the last reported quarterly earnings per share in its October 16, 2026 earnings overview, which linked the next report to the third quarter.
The revenue figure gives the upcoming release a clear benchmark. MarketBeat listed USD 1.21 billion as the consensus revenue estimate for the third quarter, compared with USD 1.14 billion in the year-ago quarter, a difference of USD 70.00 million.
Stock sits inside its yearly range
Elanco traded between a 52-week low of USD 19.40 and a high of USD 27.98. The closing price was 15.83 percent below the high and 21.39 percent above the low. Trading volume reached 5,165,597 shares against an average of 6,239,962 shares.
Valuation and the next report
The company carried a market capitalization of USD 11.8 billion and a negative trailing price-to-earnings ratio of 58.87. The next earnings announcement is scheduled for November 6, 2026, before the market opens, with the conference call set for 8:00 a.m. ET, according to Elanco.
Comparison with peers
ELAN (NYSE, USD): plus 0.04 percent, P/E minus 58.87, market capitalization USD 11.8 billion
Zoetis (NYSE, USD): plus 1.15 percent, P/E 13.07, market capitalization USD 32.8 billion
IDEXX Laboratories (Nasdaq, USD): plus 2.41 percent, P/E 39.69, market capitalization USD 44.1 billion
Price and investor perspective
The Goldman Sachs target places the latest closing price below a USD 32.00 valuation marker, while the next earnings date provides the next scheduled company checkpoint. Elanco stock remains within its 52-week range, with the high still USD 4.43 above the latest close.
The further course of trading is shown by the continuously updated real-time quote of Elanco Animal Health stock.
Elanco Animal Health stock facts
- Company: Elanco Animal Health Incorporated
- ISIN: US28414H1032
- Ticker: ELAN
- Primary exchange: NYSE
- Price on the NYSE: USD 23.55 at 4:00 p.m. ET on October 16, 2026
- Change versus prior close: plus 0.04 percent
- Market capitalization: USD 11.8 billion as of October 16, 2026
- 52-week range: USD 19.40-27.98 as of October 16, 2026
- Sector / Industry: Healthcare / Specialty and Generic Drugs
- Next earnings date: November 6, 2026
Market context: Market report S&P 500.
